Home > Healthcare > Pharmaceuticals > Finished Drug Form > Myeloproliferative Disorders Drugs/Treatment Market

Myeloproliferative Disorders Drugs/Treatment Market Share

Report ID: GMI8372
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Myeloproliferative Disorders Drugs/Treatment Market Share

Several key players are intensely involved in R&D activities aimed at introducing cutting-edge treatments for myeloproliferative disorders. These companies prioritize the development of targeted therapies such as JAK inhibitors in their pursuit of capturing market share. Additionally, they actively pursue collaborative research efforts and seek market authorization for effective treatment options to establish and uphold their leading position in the fiercely competitive market landscape.

Myeloproliferative Disorders Drugs/Treatment Market Companies

Prominent players operating in the myeloproliferative disorders drugs/treatment industry are as mentioned below:

AbbVie Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
GlaxoSmithKline plc (GSK)
GL Pharma GmbH
Incyte Corporation
Janssen Biotech, Inc. (Johnson & Johnson)
MorphoSys AG
Mylan N.V. (Viatris)
Novartis Pharmaceuticals Corporation (Novartis AG)
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of myeloproliferative disorders drugs/treatment reached USD 9.3 billion in revenue in 2023 and is set to witness 3.2% CAGR through 2032, driven by the increasing availability of novel drugs worldwide.

The JAK inhibitors segment is anticipated to witness 3.1% CAGR over 2024-2032, owing to the growing research on introducing effective treatments for the rare hematological disorder.

North America market accounted for 41.9% revenue share in 2023, owing to the presence of advanced healthcare infrastructure and facilities in the region.

Some top myeloproliferative disorders drugs/treatment firms are AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc (GSK), GL Pharma Gmb, Incyte Corporation, Janssen Biotech, Inc. (Johnson & Johnson), MorphoSys AG, Mylan N.V. (Viatris), Novartis Pharmaceuticals Corporation (Novartis AG), Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.